Introduction
============

Endometrial cancer is showing rapid increases in mortality and incidence in Japan ([@b1-ol-07-04-1109]). Previous clinicopathological studies have shown that poor prognosis of endometrial cancer is associated with the histological grade of the tumour, presence of malignant cells in ascites or the washing of specimens for cytology, cervical invasion of malignant cells, deep myometrial invasion of malignant cells, lymph node metastasis and involvement of malignant cells in the lymphovascular space ([@b2-ol-07-04-1109]--[@b4-ol-07-04-1109]).

Obesity is a well-established risk factor associated with several types of cancer, including endometrial cancer ([@b5-ol-07-04-1109]--[@b8-ol-07-04-1109]). The factor linking obesity to endometrial cancer appears to be excessive exposure to various factors produced by adipose tissue. Adipose tissue is a source of oestrogen, insulin and insulin-like growth factors, all of which are considered to be involved in endometrial tumourigenesis ([@b9-ol-07-04-1109],[@b10-ol-07-04-1109]). In addition to these factors, adipose tissues produce various bioactive hormones called adipokines, the most prominent of which are leptin and adiponectin. These may significantly influence the growth and proliferation of tumours ([@b11-ol-07-04-1109]--[@b13-ol-07-04-1109]).

Leptin, a product of the obese (Ob) gene, is produced predominantly in adipose tissue and expressed in normal tissues and malignant breast tissues ([@b14-ol-07-04-1109]--[@b16-ol-07-04-1109]). Expression of leptin and leptin receptor (ObR) is more frequent in carcinoma than in normal tissue ([@b17-ol-07-04-1109],[@b18-ol-07-04-1109]). Leptin is involved in a variety of functions, including appetite regulation, bone formation, reproduction and angiogenesis ([@b19-ol-07-04-1109]), and may affect processes associated with cancer initiation and progression, resulting in the development of metastases ([@b15-ol-07-04-1109],[@b17-ol-07-04-1109],[@b20-ol-07-04-1109],[@b21-ol-07-04-1109]). Leptin acts through ObR, which is encoded by the Ob gene. Binding of leptin to ObR activates the Janus kinase (JAK)/signal transducer and activator of transcription signalling pathway and induction of JAK stimulates phosphoinositol-3-kinase (PI3-kinase). Activation of PI3-kinase increases cell migration and invasion via the Rac/Rho pathways and stimulates the major growth and survival Akt pathway ([@b13-ol-07-04-1109]).

Adiponectin is an additional type of adipocytokine, predominantly secreted by adipocytes ([@b12-ol-07-04-1109]). In contrast to other adipocytokines, adiponectin levels correlate inversely with central fat accumulation ([@b22-ol-07-04-1109]). Adiponectin may exert antineoplastic activity through suppression of tumour proliferation and neoangiogenesis, and through induction of apoptosis ([@b23-ol-07-04-1109]--[@b25-ol-07-04-1109]). In addition, an inverse correlation has been found between plasma adiponectin levels and the histological grade of endometrial cancer ([@b26-ol-07-04-1109]). However, the precise effects of adiponectin in endometrial cancer remain unclear. In total, two adiponectin receptors (AdipoR-1 and AdipoR-2) have been identified and *in vitro* studies have shown that the two AdipoR genes are expressed in human monocytes, macrophages, adipocytes, vascular smooth muscles, a primary osteoblast cell line, pancreatic cells and other cell types ([@b27-ol-07-04-1109]--[@b30-ol-07-04-1109]). Previous *in vivo* studies have shown that AdipoR-1 is abundantly expressed in skeletal muscle and the liver, whereas AdipoR-2 is predominantly expressed in the liver. Additionally, AdipoR-1 in the liver activates AMP-activated protein kinase pathways, while AdipoR-2 activates peroxisome proliferator-activated receptor pathways ([@b27-ol-07-04-1109],[@b31-ol-07-04-1109],[@b32-ol-07-04-1109]). In addition, expression of AdipoR has previously been documented in several human cancer cell lines ([@b33-ol-07-04-1109],[@b34-ol-07-04-1109]).

The aim of the present study was to determine whether the immunohistochemical expression of AdipoR-1, AdipoR-2 or ObR correlates with the clinicopathological manifestations and clinical outcomes of endometrial carcinoma patients.

Materials and methods
=====================

Clinical samples
----------------

Formalin-fixed, paraffin-embedded tumour tissues were obtained from 77 patients with endometrioid adenocarcinoma of the endometrium. All patients attended the Gynaecology Clinic at the Aichi Medical University Hospital (Nagakute, Japan) and were diagnosed with endometrial endometrioid adenocarcinoma based on post-surgical assessment. Clinicopathological characteristics of the patients are shown in [Table I](#tI-ol-07-04-1109){ref-type="table"}. Normal endometrial tissue was also obtained from 19 patients with benign uterine disease (uterine leiomyoma, n=12; and uterine prolapse, n=7). All study protocols were approved by the regional ethics committee of the Aichi Medical University, School of Medicine (Nagakute, Japan). Written informed consent was obtained from all participants prior to study enrolment.

Immunohistochemistry
--------------------

The prepared 3-μm sections were deparaffinised and rehydrated. Following microwave processing for 25 min in 10 mM citrate buffer (pH 6.0), sections were incubated for 30 min in methanol containing 0.5% H~2~O~2~. Following incubation in normal goat serum for 1 h at room temperature to block non-specific staining, slides were incubated overnight with the primary antibodies at 4°C. The primary antibodies used were rabbit anti-human AdipoR-1 (raised against amino acid residues 357--375) antiserum, rabbit anti-human AdipoR-2 (raised against amino acid residues 374--386) antiserum (both purchased from Phoenix Pharmaceuticals, Burlingame, CA, USA) and rabbit anti-human ObR (raised against amino acid residues 541--840) antiserum (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), used at dilutions of 1:500, 1:200 and 1:200, respectively. Anti-rabbit antibody-labelled polymer horseradish peroxidase (ChemMate Envision kit; Dako Japan, Kyoto, Japan) was used as the secondary antibody, applied for 30 min at room temperature. The horseradish peroxidase reaction was developed with 3,3′-diaminobenzidine tetrahydrochloride (Katayama Chemical Industries Co. Ltd., Osaka, Japan)and sections were counterstained with haematoxylin (Katayama Chemical Industries Co. Ltd.) for microscopic examination (Olympus BX50, Olympus Corp., Tokyo, Japan). Sections were defined as showing positive expression when \>50% of tumour cells were intensely stained.

Statistical analysis
--------------------

The statistical significance of differences among different categories of expression was analysed using the χ^2^ test and two-way analysis of variance. Progression-free and overall survival were analysed using the Kaplan-Meier method and log-rank test, and the potential significance of multiple prognostic factors for progression-free and overall survival were analysed by the Cox proportional hazard regression test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

AdipoR-1, AdipoR-2 and ObR localisation
---------------------------------------

AdipoR-1, AdipoR-2 and ObR were localised predominantly to the cell membrane and cytoplasm of tumour cells ([Fig. 1](#f1-ol-07-04-1109){ref-type="fig"}). In normal endometrial tissue, the expression of AdipoR-1, AdipoR-2 and ObR was identified in endometrial glandular cells, in the proliferative and secretory phases. Expression of AdipoR-1 was found in nine of the 10 proliferative-phase specimens and in all nine secretory-phase specimens. In addition, the expression of AdipoR-2 and ObR were found in all 10 proliferative-phase and nine secretory-phase specimens.

AdipoR-1, AdipoR-2 and ObR expression
-------------------------------------

In the 77 endometrial cancer cases, positive expression was observed in 46 cases (59.7%) for AdipoR-1, 47 cases (61.0%) for AdipoR-2 and 33 cases (42.9%) for ObR. Expression of AdipoR-1 was observed most in stage I cases versus stage II or III cases, G1 tumours versus G2 or G3 tumours, tumours with shallow myometrial invasion versus tumours with deep myometrial invasion, tumours with negative lymphovascular space involvement versus tumours with positive lymphovascular space involvement, cases with negative adnexal invasion versus cases with positive adnexal invasion and cases with negative lymph node metastasis versus cases with positive lymph node metastasis. Conversely, cervical stromal invasion, peritoneal cytology and body mass index exhibited no correlation with AdipoR-1 expression ([Table II](#tII-ol-07-04-1109){ref-type="table"}). However, expression of AdipoR-2 appeared unrelated to any clinicopathological factors and expression of ObR was unrelated to any factors other than tumour grade.

Survival rates
--------------

In the Kaplan-Meier analyses, progression-free and overall survival times were longer in cases with positive AdipoR-1 expression compared with negative AdipoR-1 expression, while survival time did not show any correlation with AdipoR-2 or ObR expression ([Figs. 2](#f2-ol-07-04-1109){ref-type="fig"} and [3](#f3-ol-07-04-1109){ref-type="fig"}; [Tables III](#tIII-ol-07-04-1109){ref-type="table"} and [IV](#tIV-ol-07-04-1109){ref-type="table"}).

Univariate and multivariate analyses
------------------------------------

Univariate logistic regression analysis revealed that advanced-stage disease, high tumour grade, deeper myometrial invasion, cervical stromal invasion, adnexal invasion, involvement of the lymphovascular space, lymph node metastasis and negative AdipoR-1 expression were all significantly associated with poor progression-free survival. Similarly, multivariate Cox proportional hazard regression analysis revealed adnexal invasion and lymph node metastasis as independent variables associated with shorter progression-free survival ([Table III](#tIII-ol-07-04-1109){ref-type="table"}). Univariate logistic regression analysis revealed that advanced-stage disease, high tumour grade, deeper myometrial invasion, cervical stromal invasion, adnexal invasion, lymph node metastasis and negative AdipoR-1 expression were significantly associated with poor overall survival, while multivariate Cox proportional hazard regression analysis revealed that adnexal invasion and lymph node metastasis were also identified as independent variables associated with shorter overall survival ([Table IV](#tIV-ol-07-04-1109){ref-type="table"}).

Discussion
==========

Obesity is a known risk factor for endometrial cancer ([@b8-ol-07-04-1109]). Adipose tissues produce various bioactive substances called adipokines, the most prominent of which are leptin and adiponectin. Leptin has been found to positively correlate with obesity and is a well-known regulator of food intake and energy balance. By reducing tissue sensitivity to insulin, leptin is responsible for hyperinsulinaemia ([@b35-ol-07-04-1109]). Adiponectin has been found to negatively correlate with obesity, and low levels of adiponectin have been shown to have a high correlation with hyperinsulinaemia and the degree of insulin resistance independent of adiposity ([@b36-ol-07-04-1109]). These adipokines are reportedly associated with carcinogenesis and tumour growth in several types of cancer, including breast, colon, stomach and endometrial cancer ([@b5-ol-07-04-1109]--[@b8-ol-07-04-1109]). Serum concentrations of leptin are reportedly higher, and those of adiponectin lower, in patients with endometrial cancer compared with the control subjects ([@b26-ol-07-04-1109],[@b37-ol-07-04-1109]--[@b40-ol-07-04-1109]). The balance of leptin and adiponectin levels in individuals, rather than leptin or adiponectin levels alone, may indicate such physiological changes as the development of endometrial cancer ([@b41-ol-07-04-1109]).

Previously, adiponectin has been shown to exert suppressive effects on tumour development ([@b42-ol-07-04-1109]). Low adiponectin serum concentrations have been identified in patients affected by cancer ([@b38-ol-07-04-1109],[@b42-ol-07-04-1109]--[@b44-ol-07-04-1109]), including endometrial cancer. Serum adiponectin levels have been found to be inversely and independently associated with endometrial cancer ([@b39-ol-07-04-1109]).

The actions of adiponectin are mediated by binding to two receptors, AdipoR-1 and AdipoR-2 ([@b31-ol-07-04-1109]), and leptin actions are also mediated by binding to ObR.

Adiponectin has been previously reported to suppress endometrial cancer proliferation through AdipoRs and also increase the expression of the adaptor molecule, *LKB1*, which is required for adiponectin-mediated activation of the AMPK/S6 axis and modulation of cell proliferation, colony formation, adhesion and invasion of endometrial carcinoma cell lines *in vitro* ([@b34-ol-07-04-1109],[@b45-ol-07-04-1109]). In addition, adiponectin reportedly acts to potently inhibit endothelial cell proliferation and migration *in vitro* and, in chick chorioallantoic membrane and mouse corneal angiogenesis assays, adiponectin shows marked activity in preventing new blood vessel growth. Furthermore, the antiendothelial mechanisms have been demonstrated to involve the activation of caspase-mediated endothelial cell apoptosis. Adiponectin induces the cascade activation of caspase-8, -9 and -3, leading to cell death. In a previous mouse tumour model, adiponectin significantly inhibited primary tumour growth ([@b23-ol-07-04-1109]). Impaired tumour growth appeared to be associated with decreased neovascularisation, leading to significantly increased tumour cell apoptosis. These results demonstrated the induction of endothelial apoptosis as an unique mechanism for adiponectin-induced antiangiogenesis. Adiponectin, as a direct endogenous angiogenesis inhibitor, may have therapeutic implications in the treatment of angiogenesis-dependent diseases, including endometrial cancer ([@b23-ol-07-04-1109]).

The expression of these receptors has previously been documented in normal endometrium ([@b46-ol-07-04-1109]) and endometrial cancer tissues ([@b47-ol-07-04-1109]), but the role of AdipoR-1, AdipoR-2 and ObR in endometrial carcinoma has not been fully determined.

The present study demonstrated that AdipoR-1, AdipoR-2 and ObR are expressed in endometrial carcinoma tissue, and that AdipoR-1 expression inversely correlates with high histological grade, deep myometrial invasion, involvement of the lymphovascular space, adnexal invasion and lymph node metastasis, and is associated with improved progression-free and overall survival. However, AdipoR-2 and ObR expression was not found to correlate with any clinicopathological factors or survival in patients with endometrial carcinoma. Immunohistochemical expression of adiponectin in paired samples of endometrial carcinoma was also examined, but failed to observe any adiponectin expression in tumour cells or stromal elements (data not shown). Thus, the present results suggested that autocrine and paracrine stimulations of AdipoRs are unsuitable for endometrial carcinoma.

Previously, Yamauchi *et al* ([@b47-ol-07-04-1109]) reported that decreased AdipoR-1 expression significantly correlates with higher histological grade, myometrial invasion and lymph node metastasis of endometrioid adenocarcinoma. These results raised the possibility that the decreased expression of AdipoRs is implicated in the development, invasion and metastasis of human endometrioid adenocarcinoma. Thus, AdipoRs may be considered as therapeutic targets for endometrioid adenocarcinoma. In AdipoR-positive endometrioid adenocarcinoma, adiponectin-based anticancer therapy may prove useful. In addition, Yamauchi *et al* ([@b47-ol-07-04-1109]) commented that AdipoR-1 and AdipoR-2 may be considered as therapeutic targets for endometrioid adenocarcinomas. Methods leading to the upregulation of AdipoRs or development of specific AdipoR agonists (such as osmotin) may prove beneficial in the treatment of endometrioid adenocarcinomas, and the results of the current study appear to support this perspective.

Several limitations must be considered when interpreting the results of the present study. Firstly, the immunohistochemical expression of AdipoR-1, AdipoR-2 and ObR were analysed, but gene and protein expression levels were not revealed in endometrial carcinoma. Secondly, the present study was unable to assume that correlations exist between serum adiponectin or leptin levels and the expression of AdipoRs and ObR in patients with endometrial carcinoma. Despite these limitations, we considered the present observations to be meaningful, since they provide evidence that AdipoR-1 levels are inversely correlated with the biologically malignant phenotypes of endometrial carcinoma, and that endometrial cancer patients with positive expression of AdipoR-1 experience an improved prognosis in terms of progression-free and overall survival.

In conclusion, the present study demonstrated the expression of AdipoR-1, AdipoR-2 and ObR in human endometrioid adenocarcinoma of the uterine corpus. In addition, the decreased expression of AdipoR-1 molecules was associated with tumour growth, invasion and metastasis, representing factors predictive of poor prognosis in patients with endometrial carcinoma. Furthermore, adiponectin-based anticancer therapies may prove useful for treating endometrial cancer.

![Representative examples of immunohistochemical visualisation of AdipoR-1, AdipoR-2 and ObR in endometrial carcinoma. (A) AdipoR-1 expression in G2 endometrioid adenocarcinoma and (B) AdipoR-2 and (C) ObR expression in G1 endometrioid adenocarcinoma. AdipoR-1, adiponectin receptor type 1; AdipoR-2, adiponectin receptor type 2; ObR, leptin receptor. Magnification, ×200.](OL-07-04-1109-g00){#f1-ol-07-04-1109}

![PFS was analysed using the Kaplan-Meier method and compared in relation to AdipoR-1, AdipoR-2 and ObR expression. PFS, progression-free survival; AdipoR-1, adiponectin receptor type 1; AdipoR-2, adiponectin receptor type 2; ObR, leptin receptor.](OL-07-04-1109-g01){#f2-ol-07-04-1109}

![OS was analysed using the Kaplan-Meier method and compared in relation to AdipoR-1, AdipoR-2 and ObR expression. OS, overall survival; AdipoR-1, adiponectin receptor type 1; AdipoR-2, adiponectin receptor type 2; ObR, leptin receptor.](OL-07-04-1109-g02){#f3-ol-07-04-1109}

###### 

Characteristics of 77 patients with endometrioid adenocarcinoma of the endometrium.

  Characteristics                    n
  ---------------------------------- ------------
  Stage                              
   IA                                30
   IB                                23
   II                                9
   IIIA                              2
   IIIC                              13
  Grade                              
   G1                                39
   G2                                22
   G3                                16
  Myometrial invasion                
   \<1/2                             38
   ≥1/2                              39
  Cervical stromal invasion          
   Negative                          59
   Positive                          18
  Adnexal invasion                   
   Negative                          69
   Positive                          8
  Lymphovascular space involvement   
   Negative                          52
   Positive                          25
  Lymph node metastasis              
   Negative                          65
   Positive                          12
  Peritoneal cytology                
   Negative                          61
   Positive                          16
  Body mass index, kg/m^2^           
   \<25                              45
   ≥25 to \<30                       16
   ≥30 to \<35                       9
   ≥35                               7
  Adjuvant therapy                   
   None                              26
   Radiotherapy                      12
   Chemotherapy                      39
   AP                                9
   TJ                                30
  Age, years (mean ± SD)             56.91±9.98

AP, doxorubicin + cisplatin; TJ, paclitaxel + carboplatin.

###### 

Clinicopathological characteristics in relation to the immunohistochemical expression of AdipoR-1, AdipoR-2 and ObR in tumours obtained from 77 patients with endometrial carcinoma.

  Clinicopathological characteristics   n    AdipoR-1, n (%)   AdipoR-2, n (%)   ObR, n (%)
  ------------------------------------- ---- ----------------- ----------------- ------------
  Stage                                                                          
   IA                                   30   23 (76.7)         18 (60.0)         10 (33.3)
   IB                                   23   14 (60.9)         14 (60.9)         13 (56.5)
   II                                   9    6 (66.7)          6 (66.7)          4 (44.4)
   IIIA                                 2    0 (0.0)           2 (100)           0 (0.0)
   IIIC                                 13   3 (23.1)          7 (53.8)          6 (46.2)
                                             P=0.0073          P=0.7920          P=0.3507
  Grade                                                                          
   G1                                   39   34 (87.2)         27 (69.2)         18 (46.2)
   G2                                   22   10 (45.5)         14 (63.6)         13 (59.1)
   G3                                   16   2 (12.5)          6 (37.5)          2 (12.5)
                                             P\<0.0001         P=0.0867          P=0.0138
  Myometrial invasion                                                            
   \<1/2                                38   29 (76.3)         24 (63.2)         14 (36.8)
   ≥1/2                                 39   17 (43.6)         23 (59.0)         19 (48.7)
                                             P=0.0051          P=0.8162          P=0.3594
  Cervical stromal invasion                                                      
   Negative                             59   38 (64.4)         35 (59.3)         25 (42.4)
   Positive                             18   8 (44.4)          12 (66.7)         8 (44.4)
                                             P=0.1720          P=0.7831          P=0.8765
  Adnexal invasion                                                               
   Negative                             69   46 (66.7)         42 (60.9)         31 (44.9)
   Positive                             8    0 (0.0)           5 (62.5)          2 (25.0)
                                             P=0.0004          P=0.9287          P=0.4544
  Lymphovascular space involvement                                               
   Negative                             52   39 (75.0)         35 (67.3)         25 (48.1)
   Positive                             25   7 (28.0)          12 (48.0)         8 (32.0)
                                             P=0.0001          P=0.1360          P=0.2235
  Lymph node metastasis                                                          
   Negative                             65   44 (67.7)         41 (63.1)         27 (41.5)
   Positive                             12   2 (29.2)          6 (50.0)          6 (50.0)
                                             P=0.0024          P=0.5216          P=0.7526
  Peritoneal cytology                                                            
   Negative                             61   37 (60.7)         36 (59.0)         27 (44.3)
   Positive                             16   9 (56.3)          11 (68.8)         6 (37.5)
                                             P=0.7805          P=0.5722          P=0.7785
  BMI, kg/m^2^                                                                   
   \<25                                 45   27 (60)           29 (64.4)         20 (44.4)
   ≥25                                  32   19 (59.4)         18 (56.3)         13 (40.6)
                                             P=0.9560          P=0.4872          P=0.8172
  Total                                 77   46 (59.7)         47 (61.0)         33 (42.9)

AdipoR-1, adiponectin receptor type 1; AdipoR-2, adiponectin receptor type 2; ObR, leptin receptor; BMI, body mass index.

###### 

Uni- and multivariate analyses of variables associated with progression-free survival using the Kaplan-Meier method with log-rank test, logistic regression model and Cox proportional hazard model.

                                          Kaplan-Meier method   Univariate analysis   Multivariate analysis                                                      
  ---------------------------------- ---- --------------------- --------------------- ----------------------- --------------- ---------- -------- -------------- --------
  Stage                                                                                                                                                          
   I                                 53   92.10                 \<0.0001              −1.012                  0.218--0.608    0.0001     −0.554   0.130--2.540   0.4648
   II/III                            24   49.20                                                                                                                  
  Grade                                                                                                                                                          
   G1/G2                             61   88.50                 \<0.0001              −1.934                  0.055--0.381    \<0.0001   −0.124   0.397--1.967   0.7615
   G3                                16   43.80                                                                                                                  
  Myometrial invasion                                                                                                                                            
   \<1/2                             38   92.10                 0.004                 −1.642                  0.056--0.675    0.0099     0.302    0.675--2.708   0.394
   ≤1/2                              39   66.20                                                                                                                  
  Cervical stromal invasion                                                                                                                                      
   Negative                          59   87.80                 0.00001               −1.724                  0.066--0.483    0.0007     −0.457   0.222--1.808   0.3932
   Positive                          18   48.60                                                                                                                  
  Adnexal invasion                                                                                                                                               
   Negative                          69   86.50                 \<0.0001              −2.957                  0.017--0.154    \<0.0001   −2.086   0.030--0.508   0.0037
   Positive                          8    12.50                                                                                                                  
  Lymphovascular space involvement                                                                                                                               
   Negative                          52   85.90                 0.0216                −1.067                  0.133--0.893    0.0283     −0.005   0.495--1.998   0.9881
   Positive                          25   63.80                                                                                                                  
  Lymph node metastasis                                                                                                                                          
   Negative                          65   90.40                 \<0.0001              −2.921                  0.018--0.157    \<0.0001   −1.953   0.040--0.509   0.0027
   Positive                          12   12.50                                                                                                                  
  Peritoneal cytology                                                                                                                                            
   Negative                          61   81.60                 0.237                 −0.623                  0.188--1.531    0.2445     0.635    0.605--5.886   0.2741
   Positive                          16   67.50                                                                                                                  
  AdipoR-1 expression                                                                                                                                            
   Negative                          31   59.90                 0.0004                1.780                   1.928--18.246   0.0019     −0.068   0.454--1.921   0.8525
   Positive                          46   91.20                                                                                                                  
  AdipoR-2 expression                                                                                                                                            
   Negative                          30   75.90                 0.9722                0.017                   0.384--2.697    0.9722     −0.363   0.361--1.340   0.2779
   Positive                          47   80.90                                                                                                                  
  ObR expression                                                                                                                                                 
   Negative                          44   79.20                 0.945                 0.034                   0.393--2.723    0.945      −0.218   0.409--1.580   0.5273
   Positive                          33   78.30                                                                                                                  
  BMI, kg/m^2^                                                                                                                                                   
   \<25                              45   82.20                 0.3527                0.126                   0.716--1.797    0.5907     −0.069   0.570--1.529   0.7834
   ≥25                               32   74.00                                                                                                                  
  Age, years                                                                                                                                                     
  \<60                               45   79.50                 0.9015                −0.042                  0.606--1.516    0.8567     0.083    0.549--2.151   0.8121

HR, hazard ratio; CI, confidence interval; AdipoR-1, adiponectin receptor type 1; AdipoR-2, adiponectin receptor type 2; ObR, leptin receptor; BMI, body mass index.

###### 

Uni- and multivariate analyses of variables associated with overall survival using the Kaplan-Meier method with log-rank test, logistic regression model and Cox proportional hazard model.

                                          Kaplan-Meier method   Univariate analysis   Multivariate analysis                                                      
  ---------------------------------- ---- --------------------- --------------------- ----------------------- --------------- ---------- -------- -------------- --------
  Stage                                                                                                                                                          
   I                                 53   100                   \<0.0001              −0.894                  0.244--0.687    0.0007     −0.871   0.097--1.808   0.2431
   II/III                            24   70.80                                                                                                                  
  Grade                                                                                                                                                          
   G1/G2                             61   95.1                  0.0101                −1.575                  0.055--0.777    0.0196     0.655    0.838--4.422   0.1228
   G3                                16   75.0                                                                                                                   
  Myometrial invasion                                                                                                                                            
   \<1/2                             38   100                   0.0177                −2.106                  0.015--0.974    0.0472     0.208    0.616--2.461   0.5566
   ≥1/2                              39   82.10                                                                                                                  
  Cervical stromal invasion                                                                                                                                      
   Negative                          59   94.90                 0.0078                −1.653                  0.049--0.741    0.0166     0.837    0.748--7.123   0.1454
   Positive                          18   77.80                                                                                                                  
  Adnexal invasion                                                                                                                                               
   Negative                          69   98.60                 \<0.0001              −3.867                  0.004--0.108    \<0.0001   −2.266   0.032--0.340   0.0002
   Positive                          8    25.0                                                                                                                   
  Lymphovascular space involvement                                                                                                                               
   Negative                          52   96.20                 0.0607                −1.156                  0.088--1.125    0.0752     0.192    0.577--2.545   0.6125
   Positive                          25   80.0                                                                                                                   
  Lymph node metastasis                                                                                                                                          
   Negative                          65   100                   \<0.0001              −4.510                  0.001--0.093    \<0.0001   −1.193   0.107--0.860   0.0248
   Positive                          12   41.70                                                                                                                  
  Peritoneal cytology                                                                                                                                            
   Negative                          61   93.40                 0.0368                −1.313                  0.072--1.009    0.0515     −0.109   0.332--2.425   0.8306
   Positive                          16   81.30                                                                                                                  
  AdipoR-1 expression                                                                                                                                            
   Negative                          31   77.40                 0.0018                2.565                   1.620--10.427   0.0158     0.026    0.478--2.202   0.947
   Positive                          46   100                                                                                                                    
  AdipoR-2 expression                                                                                                                                            
   Negative                          30   86.70                 0.3374                0.637                   0.504--7.092    0.3453     0.387    0.796--2.726   0.2176
   Positive                          47   93.60                                                                                                                  
  ObR expression                                                                                                                                                 
   Negative                          44   90.90                 0.3605                −0.608                  0.145--2.043    0.3676     −0.432   0.321--1.312   0.2284
   Positive                          33   90.90                                                                                                                  
  BMI, kg/m^2^                                                                                                                                                   
   \<25                              45   91.10                 0.2739                0.095                   0.696--1.737    0.685      0.034    0.610--1.754   0.8988
   ≥25                               32   90.60                                                                                                                  
  Age, years                                                                                                                                                     
   \<60                              45   91.10                 0.9348                −0.024                  0.617--1.546    0.9186     −0.192   0.417--1.636   0.5828
   ≥60                               32   90.60                                                                                                                  

HR, hazard ratio; CI, confidence interval; AdipoR-1, adiponectin receptor type 1; AdipoR-2, adiponectin receptor type 2; ObR, leptin receptor; BMI, body mass index.
